Amicus Therapeutics Announces Closing of Underwritten Offering of Common Stock
05 June 2019 - 6:01AM
Amicus Therapeutics (Nasdaq: FOLD) today announced the closing of
its previously announced offering of common stock. The Company
issued a total of 18,720,930 shares of its common stock, including
2,441,860 shares of common stock sold pursuant to the underwriters’
full exercise of their option to purchase additional shares, at a
public offering price of $10.75 per share.
The gross proceeds from the offering to Amicus
are expected to be $201 million, before deducting underwriting
discounts and commissions and offering expenses payable by Amicus.
J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and SVB
Leerink LLC acted as joint book-running managers for the
offering.
The Company expects to use the net proceeds of
the offering for investment in the development of the expanded gene
therapy pipeline, manufacturing capabilities for Pompe biologic
AT-GAA and gene therapy product candidates, including contract
manufacturing partnerships, completion of the design and build of
the Amicus Process Science and Gene Therapy Manufacturing facility
and for other general corporate and product development
purposes.
Copies of the prospectus supplement and
accompanying base prospectus relating to the offering may be
obtained by contacting J.P. Morgan Securities LLC, c/o Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, New York
11717 (telephone number: 866-803-9204), Goldman Sachs & Co.
LLC, by mail, Attn: Prospectus Department, 200 West Street, New
York, NY 10282, by facsimile: 212-902-9316, by email:
prospectus-ny@ny.email.gs.com; or by telephone: 866-471-2526, or
SVB Leerink LLC, Attention: Syndicate Department, One Federal
Street, 37th Floor, Boston, MA 02110, or by telephone at (800)
808-7525, ext. 6132, or by email at syndicate@svbleerink.com.
About Amicus Therapeutics Amicus Therapeutics
(Nasdaq: FOLD) is a global, patient-dedicated biotechnology company
focused on discovering, developing and delivering novel
high-quality medicines for people living with rare metabolic
diseases. With extraordinary patient focus, Amicus
Therapeutics is committed to advancing and expanding a robust
pipeline of cutting-edge, first- or best-in-class medicines for
rare metabolic diseases.
Forward-Looking StatementsStatements regarding
the proposed public offering constitute forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. There can
be no assurance that Amicus will be able to complete the proposed
offering of common stock on acceptable terms, or at all.
Actual results or events may differ materially from those indicated
by forward-looking statements as a result of various risks,
uncertainties and important factors, including those set forth in
the “Risk Factors” section in the preliminary prospectus supplement
relating to the offering. In addition, all forward-looking
statements are subject to other risks detailed in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2018 and
Quarterly Report on Form 10-Q for the quarter ended March 31,
2019. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, and Amicus undertakes no
obligation to revise or update this news release to reflect events
or circumstances after the date hereof.
CONTACTS:
Investors/Media:Amicus TherapeuticsSara
Pellegrino, IRCVice President, Investor Relations & Corporate
Communicationsspellegrino@amicusrx.com (609) 662-5044
Media:Amicus TherapeuticsMarco WinklerDirector,
Corporate Communicationsmwinkler@amicusrx.com(609) 662-2798
FOLD–G
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From Apr 2024 to May 2024
Amicus Therapeutics (NASDAQ:FOLD)
Historical Stock Chart
From May 2023 to May 2024